Adicet Bio Inc. (NASDAQ:ACET) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in autoimmune diseases showed encouraging signs.The company priced a registered direct offering of 70 million shares and pre-funded warrants to purchase 10 million shares at$1.00 per share and $0.9999 per warrant, respectively, for expected gross proceeds of approximately$80 million.The stock climbed as high as $1. ...